To print: Select File and then Print from your browser's menu

Title: Concomitant Leflunomide Improves Response to Methotrexate in Patients with Persistent Rheumatoid Arthritis

URL: http://www.annals.org/issues/v137n9/abs/200211050-00007.html

Annals of Internal Medicine 2002;137(9):726-733. "Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate. A Randomized, Double-Blind, Placebo-Controlled Trial"
11/08/2002 03:27:09 PM
By David Loshak

Addition of leflunomide to methotrexate provides statistically significant clinical benefit to patients with persistent rheumatoid arthritis who do not respond to methotrexate alone. This combination is generally well tolerated, report specialists at 20 leading centres in the United States and Canada. The combination can be used safely with appropriate liver enzyme and haematological monitoring, they say. Their study assessed the efficacy and safety of leflunomide, a disease-modifying anti-rheumatic drug, versus placebo when added to ongoing, stable-dose methotrexate, an antimetabolite agent, in a 24-week, randomised, double-blind trial. Patients had had persistently active rheumatoid arthritis as defined by standard American College of Rheumatology criteria that did not respond to at least six months of methotrexate treatment. The primary efficacy variable was the rate of achievement of a 20 percent improvement in American College of Rheumatology criteria (ACR20) at the end of the study. The Health Assessment Questionnaire Disability Index was determined at each visit and the Medical Outcomes Study 36-Item Short Form was completed as an end point analysis. At 24 weeks, 46.2 percent of patients given leflunomide met ACR20 criteria compared with 19.5 percent of those given placebo (p<0.001). Clinical improvement was shown by statistically significant mean changes in individual components of the ACR20 response criteria. The two groups had similar discontinuation rates (23.1 versus 24.8 percent.) and incidences of adverse events (89.2 versus 89.5 percent), which were chiefly mild or moderate.

http://www.annals.org/issues/v137n9/abs/200211050-00007.html

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.